Siegbahn, Agneta

Common variants associated with plasma triglycerides and risk for coronary artery disease

Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 862

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

Folkersen, L., Gustafsson, S., Wang, Q., Hansen, D. H., Hedman, Å. K., Schork, A., Page, K., Zhernakova, D. V., Wu, Y., Peters, J., et al. (2020) · Nature Metabolism

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 705

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., et al. (2012) · Circulation

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 402

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., et al. (2014) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 396

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., & Wallentin, L. (2013) · European Heart Journal

Atrial Fibrillation Management and OutcomesInflammatory Biomarkers in Disease Prognosis

Cited by 298

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., et al. (2013) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 231

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

Erlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesPlatelet Disorders and Treatments

Cited by 215